Business Wire

Safety results from large real-world safety study in combined oral contraception published

Share

For Medical & Business/Industry Trade Media and Investors outside the US and Canada Only

Theramex, a global women’s health company, today announced that the safety results from the PRO-E2 real-world safety study for Zoely® (NOMAC-E2) have been published in The European Journal of Contraception and Reproductive Health Care (EJCRH).1

The post-authorisation safety study (PASS), known as PRO-E2, was a large, prospective, non-interventional controlled cohort study of over 101,000 women. PRO-E2 compared the risks of using NOMAC-E2 versus COCs containing levonorgestrel (COC-LNG), a commonly prescribed contraceptive.1

The primary objective of the real-world study was to assess and compare the risk of cardiovascular events* in NOMAC-E2 users with COC-LNG users. For the main clinical outcome, the risk of VTE was as least as low with NOMAC-E2 as with COC-LNG, consistent with findings of previous studies (0.59 Hazard Ratio [HR]† 95% confidence interval [CI], 0.25-1.35).1

PRO-E2 also demonstrated that contraceptive failure (the risk of unintended pregnancy), a key secondary outcome, was statistically significantly lower with NOMAC-E2 compared with COC-LNG (0.45 HR†, 95% CI, 0.34-0.60, [p<0.0001]). Further analyses showed that the lower rate of unintended pregnancy with NOMAC-E2 was even more pronounced in women under 35 years of age.2 The shorter hormone-free interval with NOMAC-E2, its longer half-life, and monophasic regimen may all contribute to fewer unintended pregnancies.5,6,7 These results will be published in the EJCRH later this month.

All 14 secondary outcomes of the study were met, with the risk of severe adverse events and depressive disorders or changes in weight or acne score with NOMAC-E2 comparable to COC-LNG.2

Dr Joaquim Calaf Alsina, Honorary Professor of Obstetrics and Gynaecology at the Autonomous University of Barcelona, Spain, said: “This is an exciting real-world study which confirms what we suspected from both the biological profile and experience of using NOMAC-E2. This contraceptive combination has at least the same risk of VTE as the preparation shown to have the lowest risk in this aspect. The data from PRO-E2 also provides patients with important and reassuring data on efficacy and other added benefits, such as improvement of acne and low impact on body weight.”

Ms Claudine Domoney, Consultant Gynaecologist, Chelsea & Westminster Hospital, London, UK, said: “Contraception can be difficult for women and as clinicians we want to make it as easy as possible. In order to do this, there needs to be a range of options that offer reliable and convenient fertility control. The PRO-E2 study, which reflects the real-life experience of women, confirms that NOMAC-E2 is better at preventing unintended pregnancy than COC-LNG.”

Theramex CEO Robert Stewart said: “The PRO-E2 study results will build further confidence in what has already been shown to be a reliable and effective birth-control option. As a company dedicated to improving women’s health, we are delighted that the wealth of evidence from this safety study can help clinicians and women make informed decisions about contraception.”

The safety and efficacy publications were accepted by the EJCRH in September. The publication on safety results is available online:

https://www.tandfonline.com/doi/10.1080/13625187.2021.1987410

The efficacy publication will be available online later this month. Both publications will be available in the printed journal in December.

Results have also been submitted to the European Medicines Agency (EMA) and will be presented at the European Society of Gynecology congress in November this year.

Ends

Notes to Editor:

About the PRO-E2 study

PRO-E2 was designed to compare the risks of using NOMAC-E2 versus COC-LNG.8,9 VTE is an uncommon but serious adverse event linked to the use of COCs.10,11 COC-LNG was chosen as the comparator for the study as the COC associated with the lowest risk of VTE, according to treatment guidelines.12

The study, initiated by MSD and conducted by ZEG-Berlin, was required by the European Medicines Agency (EMA).8 A PASS is carried out after a medicine has been authorised to obtain further information on a medicine's safety, or to measure the effectiveness of risk- management measures.

The primary outcome was risk of VTE (specifically deep venous thrombosis of the lower extremities and pulmonary embolism).1 The secondary outcomes of interest were: all VTE, arterial thromboembolisms, idiopathic VTE, summary of VTE results, depressive disorders, mood change, cholelithiasis, inflammatory bowel disease, effect on fertility (contraceptive failure and return to fertility), pregnancy outcomes, weight change, hepatobiliary disorders, and acne.2

PRO-E2 was initiated in 2014 (following a precursor study, CELINA, initiated in 2012) and closed in December 2020.8 The results reflect real world practice in over 101,000 women (equivalent to 144,901 woman-years data) from across Australia, Austria, Colombia, France, Germany, Hungary, Italy, Mexico, Poland, Russia, Spain, and Sweden.1

About Zoely® (NOMAC-E2)

NOMAC-E2 combines nomegestrol acetate [2.5mg] and 17β-estradiol [1.5mg]. NOMAC-E2 is the only monophasic contraceptive pill using body-identical 17B-estradiol. Nomegestrol acetate (NOMAC) is a highly selective progestogen derived from the naturally occurring hormone, progesterone.3,4

MSD was exclusively licensed by Theramex to sell Zoely® in certain territories (other than the US and Canada) until January 2020 and held Marketing Authorisations for the product in the non-EU markets of such territory. In January 2020, these rights were transferred back to Theramex. The rights to sell the product in the United States and Canada pursuant to a license from Teva remained with MSD until the spin-off of Organon on June 2, 2021. Zoely® and Stezza® are brand names of 2.5mg Nomegestrol Acetate NOMAC + 1.5mg 17β- estradiol E2 Combination Oral Contraception.

About Theramex

With a broad portfolio of innovative and established brands covering contraception, fertility, menopause and osteoporosis, we support women at every stage of their lives. Our commitment is to listen and understand our patients, serve their needs, and offer healthcare solutions to help improve their lives. Our vision is to be a lifetime partner for women and the healthcare professionals who treat them, by providing innovative and effective solutions that care for and support women as they advance through each stage of their lives. www.theramex.com

References:

  1. Reed S et al. Eur J Contracept Reprod Health Care. Available from: https://www.tandfonline.com/doi/10.1080/13625187.2021.1987410 Accessed October 2021
  2. PRO-E2 final report. Available from: http://www.encepp.eu/encepp/openAttachment/studyResult/41498;jsessionid=uW82EciuLgcm015Qta9_pOv1_2skaG629DgRqfNG6I5-i02w5oS0!2052488890
  3. Theramex. (2021) Zoely® SmPC. Available from: https://www.medicines.org.uk/emc/product/3038/smpc. Accessed October 2021
  4. Westhoff C et al. ObstetGynecol 2012; 119(5):989-99.
  5. Christin-MaitreS et al. Womens Health (Lond) 2013; 9(1): 13-23.
  6. Van Vliet HAAM, Raps M. Cochrane Database Syst Rev 2011;(11): CD009038.
  7. Duijkers IJM et al. Eur J Contracept Reprod Health Care 2010; 15(5): 314-25.
  8. Clinicaltrials.gov. (2021) Prospective Controlled Cohort Study on the Safety of a Monophasic Oral Contraceptive Containing Nomegestrol Acetate (2.5mg) and 17ß-estradiol (1.5mg) (PRO-E2). Available from: https://clinicaltrials.gov/ct2/show/study/NCT01650168 Accessed October 2021
  9. Reed, S. et al. Pharmacoepidemiol Drug Saf. 2020;29(Suppl.3):4.
  10. US Food and Drug Administration. (2018). FDA Drug Safety Communication: Updated information about the risk of blood clots in women taking birth control pills containing drospirenone. Available from: www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-updated-information-about-risk-blood-clots-women-taking-birth-control. Accessed October 2021
  11. de Bastos, M. et al. (2014) Cochrane Database Syst Rev (3): CD010813.
  12. Faculty of Sexual & Reproductive Healthcare. FSRH Guideline Combined Oral Contraception. January 2019 (Amended November 2020).

*Specifically deep venous thrombosis of the lower extremities and pulmonary embolism

†HR adjusted for age, body mass index, current duration of hormonal contraceptive use, family history of VTE

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Andrew Bradley, Head of Communications, Theramex
andrew.bradley@theramex.com / +44(0) 7864 167962

Donna Gregory / Makara Health
donna@makarahealth.com / +44(0) 7917 912 271

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

The 4 th World Science and Technology Development Forum Held in Chengdu28.11.2022 17:06:00 CET | Press release

The 4th World Science and Technology Development Forum with the theme “Openness, Trust and Cooperation” kicked off in Chengdu on November 27, 2022, which was attended by more than 300 top experts and scholars, representatives of international organizations, and entrepreneurs, from more than 20 countries and regions, including 7 Nobel laureates and more than 60 academicians home and abroad. Together, they discussed technological innovation and sustainable development in key fields such as basic science, climate change, digital economy, and green innovation, and proposed technological innovation solutions to address the challenges of today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221128005539/en/ The 4th World Science and Technology Development Forum Held in Chengdu (Photo: Business Wire) The world today is facing many challenges, such as the COVID-19 pandemic, energy security, food security, climate change, poverty, an

Biocytogen Enters into Antibody Agreement with ADC Therapeutics28.11.2022 15:47:00 CET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that it has entered into an evaluation and option agreement with ADC Therapeutics SA. Biocytogen will grant ADC Therapeutics a license to evaluate Biocytogen’s proprietary antibodies against three tumor targets, with an option to license selected antibodies at a later date for global ADC development and commercialization. Biocytogen reserves all global rights for these antibodies beyond ADC development. Biocytogen will receive an upfront payment. For each option exercised, Biocytogen will be entitled to an option-exercise fee, and development and commercial milestone payments, which potentially total tens of millions of US dollars, as well as single-digit royalties on net sales. Under the agreement, Biocytogen will provide ADC Therapeutics with monoclonal and/or biparatopic antibodies directed against three tumor targets, generated through Biocytogen’s Project Integrum (also called RenMiceTM HiTS

Medimaps Group Appoints Meinhard F. Schmidt as Board Chairman; Adds Anne Le Grand and Five Additional Board Members28.11.2022 15:15:00 CET | Press release

Medimaps Group (www.medimapsgroup.com), a Swiss/Global med-tech company specializing in image processing software for assessing bone health, today announced new appointments to its Board of Directors, effective immediately. Meinhard F. Schmidt, an international MedTech/BioTech and Digital Health executive with 25+ years of experience, has been named Board Chairman; and Anne Le Grand,an accomplished healthcare executive and consultant with 30+ years in the global healthcare technology industry, has joined as an independent board member. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221128005146/en/ Medimaps Group Announces Board Members: Meinhard F. Schmidt as Board Chairman, and Anne Le Grand Plus Five Other Members and One Strategic Advisor. (Photo: Business Wire) Five additional board members and one board advisor have also been named, bolstering Medimaps investment and clinical policy expertise. Visit Medimaps website fo

Viz.ai Appoints Radiology Advisory Board to Advance Innovation28.11.2022 14:00:00 CET | Press release

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the creation of its Radiology Advisory Board to assist Viz.ai in the development of strategy and products to support radiologists and patients. The Board consists of 14 leading healthcare experts with diverse experience and roles in radiology. “I am honored to co-chair the Radiology Advisory Board and excited about Viz.ai’s commitment to customers and patients to invest in innovation that increases access to life-saving therapies,” said Kevin Abrams, MD, medical director of neuroradiology and MRI and chief of radiology at Baptist Hospital in Miami. “I am looking forward to the rich dialogue to be discussed in our inaugural meeting, exploring future ideas.” “I’m looking forward to working with these esteemed board members to help shape Viz.ai’s Radiology Program through patient-centric vision, passion, and insights,” said Suzie Bash, MD, Co-Chair of the Viz.ai Radiology Advisory Board a

Viz.ai Launches AI-powered Viz™ Radiology Suite28.11.2022 14:00:00 CET | Press release

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the introduction of an AI-powered radiology suite, specifically designed to alert the radiologist in their workflow of suspected diseases, prioritize worklists, and connect care teams in real-time. The Viz™ Radiology Suite integrates into the picture archiving and communication systems (PACS) of healthcare organizations to securely facilitate access to imaging data across departments and streamline patient diagnosis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221128005172/en/ Screen shots of Viz Radiology Suite including worklist and PACS integration (Graphic: Business Wire) “With an increasing demand for imaging studies and a global shortage of radiologists, technologies that can be easily integrated into radiology workflows to enhance efficiency and streamline patient care are sorely needed,” said Allan Brook, M.D., FA

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom